Hexosamine biosynthetic pathway promotes the antiviral activity of SAMHD1 by enhancing O-GlcNAc transferase-mediated protein O-GlcNAcylation

Theranostics. 2021 Jan 1;11(2):805-823. doi: 10.7150/thno.50230. eCollection 2021.

Abstract

Rationale: Viruses hijack the host cell machinery to promote viral replication; however, the mechanism by which metabolic reprogramming regulates innate antiviral immunity in the host remains elusive. Herein, we explore how the hexosamine biosynthesis pathway (HBP) and O-linked-N-acetylglucosaminylation (O-GlcNAcylation) regulate host antiviral response against hepatitis B virus (HBV) in vitro and in vivo.Methods: We conducted a metabolomics assay to evaluate metabolic responses of host cells to HBV infection. We systematically explored the role of HBP and protein O-GlcNAcylation in regulating HBV infection in cell and mouse models. O-linked N-acetylglucosamine (O-GlcNAc) target proteins were identified via liquid chromatography-tandem mass spectrometry (LC-MS) and co-immunoprecipitation assays. Additionally, we also examined uridine diphosphate (UDP)-GlcNAc biosynthesis and O-GlcNAcylation levels in patients with chronic hepatitis B (CHB). Results: HBV infection upregulated GLUT1 expression on the hepatocyte surface and facilitated glucose uptake, which provides substrates to HBP to synthesize UDP-GlcNAc, leading to an increase in protein O-GlcNAcylation. Pharmacological or transcriptional inhibition of HBP and O-GlcNAcylation promoted HBV replication. Mechanistically, O-GlcNAc transferase (OGT)-mediated O-GlcNAcylation of sterile alpha motif and histidine/aspartic acid domain-containing protein 1 (SAMHD1) on Ser93 stabilizes SAMHD1 and enhances its antiviral activity. Analysis of clinical samples revealed that UDP-GlcNAc level was increased, and SAMHD1 was O-GlcNAcylated in patients with CHB. Conclusions: HBP-mediated O-GlcNAcylation positively regulates host antiviral response against HBV in vitro and in vivo. The findings reveal a link between HBP, O-GlcNAc modification, and innate antiviral immunity by targeting SAMHD1.

Keywords: Hepatitis B virus; O-linked β-N-acetylglucosamine modification; antiviral immunity; hexosamine biosynthetic pathway; sterile alpha motif and histidine/aspartic acid domain-containing protein 1.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Animals
  • Antiviral Agents / pharmacology*
  • Biosynthetic Pathways*
  • Cell Proliferation
  • Female
  • Glucose / metabolism
  • Glycosylation
  • Hepatitis B / drug therapy*
  • Hepatitis B / metabolism
  • Hepatitis B / virology
  • Hepatitis B virus / drug effects*
  • Hexosamines / biosynthesis*
  • Humans
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Transgenic
  • N-Acetylglucosaminyltransferases / metabolism*
  • Protein Processing, Post-Translational
  • SAM Domain and HD Domain-Containing Protein 1 / genetics
  • SAM Domain and HD Domain-Containing Protein 1 / metabolism*

Substances

  • Antiviral Agents
  • Hexosamines
  • N-Acetylglucosaminyltransferases
  • O-GlcNAc transferase
  • SAM Domain and HD Domain-Containing Protein 1
  • SAMHD1 protein, human
  • Glucose